Table 3.

Effect of Lipid‐Lowering Therapy Intensity and Posttreatment LDL‐C on Composite Cardiovascular Events in the Population With LDL‐C ≥190 mg/dL but Without ASCVD

Variables	Posttreatment LDL‐C, mg/dL	Number of patients	Events	Duration, person‐years	Rate per 1000 person‐years	HR (95% CI) (Model 1)	P value	HR (95% CI) (Model 2)	P value
Composite events	<100	1975	56	11 485	4.88	0.75 (0.56, 1.02)	0.044	0.56 (0.41–0.76)	0.0007
	100–129	2111	92	13 515	6.81	1.05 (0.82–1.35)		0.85 (0.66–1.09)
	130–159	2448	77	15 724	4.90	0.76 (0.58–0.99)		0.69 (0.53–0.91)
	>160	4685	192	29 720	6.46	1		1
MI	<100	1975	16	11 603	1.38	0.83 (0.47–1.46)	0.86	0.71 (0.40–1.26)	0.69
	100–129	2111	25	13 707	1.82	1.09 (0.68–1.77)		0.97 (0.59–1.58)
	130–159	2448	26	15 851	1.64	0.99 (0.62–1.59)		0.93 (0.58–1.49)
	>160	4685	50	30 188	1.66	1		1
Coronary revascularization	<100	1793	35	11 546	3.03	0.87 (0.59–1.28)	0.58	0.64 (0.43–0.95)	0.058
	100–129	2111	40	13 660	2.93	0.84 (0.58–1.21)		0.68 (0.47–0.99)
	130–159	2448	44	15 792	2.79	0.80 (0.56–1.14)		0.74 (0.52–1.06)
	>160	4685	104	29 979	3.47	1		1
Ischemic stroke	<100	1975	21	11 575	1.81	0.70 (0.43–1.14)	0.016	0.51 (0.31–0.83)	0.0056
	100–129	2111	45	13 642	3.30	1.27 (0.88–1.84)		1.00 (0.68–1.45)
	130–159	2448	26	15 858	1.64	0.63 (0.41–0.99)		0.57 (0.37–0.90)
	>160	4685	78	30 134	2.59	1		1
Total mortality	<100	1975	59	11 636	5.07	1.30 (0.95–1.78)	0.35	0.81 (0.58–1.11)	0.53
	100–129	2111	65	13 764	4.72	1.21 (0.89–1.63)		0.85 (0.62–1.15)
	130–159	2448	67	15 914	4.21	1.08 (0.80–1.46)		0.96 (0.71–1.29)
	>160	4685	118	30 356	3.89	1		1

Composite events: MI, coronary revascularization, or ischemic stroke. ASCVD indicates atherosclerotic cardiovascular disease; Model 1: unadjusted. Model 2: adjusted for age, sex, body mass index, diabetes, hypertension, smoking, triglycerides, LDL‐C, and antiplatelet agents.

P values are from the Wald test for HRs of patient groups. R, hazard ratio; LDL‐C, low‐density lipoprotein‐cholesterol; and MI, myocardial infarction.